Monopar regains compliance with Nasdaq minimum bid price rule

Monopar Therapeutics

Received Nasdaq notice that closing bid price was $1.00+ for 10 consecutive trading sessions.
Compliance regained under Nasdaq Listing Rule 5550(a)(2), avoiding delisting risk.
Company remains listed on Nasdaq Capital Market under ticker MNPR.
Press release dated August 27, 2024; no other material updates provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.